58 result(s) found for: Thyroid neoplasm.
Displaying page 1 of 3.
| EudraCT Number: 2012-004295-19 | Sponsor Protocol Number: 1209-EnTF | Start Date*: 2014-10-08 | |||||||||||||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||||||||||||
| Full Title: A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line t... | |||||||||||||||||||||||
| Medical condition: Histologically confirmed differentiated or medullary thyroid cancer by local pathologist. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) IT (Completed) GB (Completed) NL (Completed) DK (Completed) FR (Completed) ES (Completed) PL (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2013-004629-96 | Sponsor Protocol Number: S-20130147 | Start Date*: 2014-06-13 | |||||||||||
| Sponsor Name:Department of Nuclear Medicine, Odense University Hospital | |||||||||||||
| Full Title: Diagnostic Modalities in Nuclear Medicine in Well-Differentiated Thyroid Cancer | |||||||||||||
| Medical condition: Well-differentiated Thyroid Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-002470-42 | Sponsor Protocol Number: 72010 | Start Date*: 2021-11-29 | |||||||||||||||||||||
| Sponsor Name:Univeristy Medical Center Utrecht | |||||||||||||||||||||||
| Full Title: Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: A proof of concept study | |||||||||||||||||||||||
| Medical condition: The IMP will be used for the identification of sentinel lymph nodes in patients with thyroid carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2013-000422-58 | Sponsor Protocol Number: D4203C00011 | Start Date*: 2013-07-02 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™) 300 mg in Patients with Papillary or Poorly Differentiated T... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Papillary Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: CZ (Completed) SE (Completed) IT (Completed) ES (Completed) DK (Completed) FR (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-003668-11 | Sponsor Protocol Number: E7080-G000-604 | Start Date*: 2018-07-30 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Eisai Ltd. | ||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: solid tumors or lymphomas, as defined in parent protocol | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-005366-17 | Sponsor Protocol Number: 2020/ABM/01/00100 | Start Date*: 2022-09-14 | |||||||||||
| Sponsor Name:Medical University of Bialystok | |||||||||||||
| Full Title: Evaluation of METtformin effect on the fertility of patients treated with 131I for THYRoid cancer – METHYR Study. | |||||||||||||
| Medical condition: Thyroid papilare cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-003814-15 | Sponsor Protocol Number: 2012-784 | Start Date*: 2013-03-06 | |||||||||||
| Sponsor Name:HOSPICES CIVILS DE LYON | |||||||||||||
| Full Title: A multicenter phase II pilot open label study to evaluate the efficacy and safety of BKM120 in the treatment of patients with advanced or metastatic differentiated thyroid cancers | |||||||||||||
| Medical condition: Follicular or poorly differentiated cancer refractory to radio iodine | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-005017-71 | Sponsor Protocol Number: CHOCOLATE | Start Date*: 2016-04-02 | |||||||||||
| Sponsor Name:Centre François Baclesse | |||||||||||||
| Full Title: Diagnostic value of 18F-choline PET in patients with indeterminate cytology thyroid nodule : A pilot study | |||||||||||||
| Medical condition: Patient with a thyroid nodule ≥15mm with indefinite cytology according to the 2008 Bethesda classification (vesicular lesion of undetermined significance; follicular neoplasm or cell Hürthle; lesi... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002269-47 | Sponsor Protocol Number: STH18441 | Start Date*: 2015-12-02 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||||||||||||||||||||||||||||||||||||||
| Full Title: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Iodine-refractory thyroid cancer of papillary, follicular, Hürthle cell or poorly differentiated carcinoma | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2005-004450-27 | Sponsor Protocol Number: THYR01605 | Start Date*: 2006-05-02 | |||||||||||
| Sponsor Name:GENZYME | |||||||||||||
| Full Title: Follow-up of Thyroid Cancer Patients from Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method | |||||||||||||
| Medical condition: Follow-up of Thyroid Cancer Patients from Study THYR-008-00 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003524-32 | Sponsor Protocol Number: NEPHENTE | Start Date*: 2023-01-11 | |||||||||||
| Sponsor Name:Istituti Clinici Scientifici Maugeri SpA Società Benefit | |||||||||||||
| Full Title: Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE) | |||||||||||||
| Medical condition: High-risk thyroid cancers | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000742-21 | Sponsor Protocol Number: 2017/2527 | Start Date*: 2017-07-31 | |||||||||||||||||||||
| Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
| Full Title: Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with... | |||||||||||||||||||||||
| Medical condition: Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients with RAS or BRAF mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2011-001386-41 | Sponsor Protocol Number: 124-I-MN-10-02 | Start Date*: 2011-06-15 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
| Full Title: Role of PET/CT with 124I for dosimetry of thyroid carcinoma before radioisotopic treatment | |||||||||||||
| Medical condition: thyroid carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002419-48 | Sponsor Protocol Number: GETNE-T2216 | Start Date*: 2023-03-27 | |||||||||||||||||||||
| Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) | |||||||||||||||||||||||
| Full Title: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. | |||||||||||||||||||||||
| Medical condition: Patients with radioiodine-refractory differentiated thyroid cancer (DTC). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2015-004535-12 | Sponsor Protocol Number: KO-TIP-001 | Start Date*: 2016-02-25 | |||||||||||||||||||||
| Sponsor Name:Kura Oncology, Inc. | |||||||||||||||||||||||
| Full Title: An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations | |||||||||||||||||||||||
| Medical condition: Advanced Non-Hematological Malignancies with HRAS mutations | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2007-005933-12 | Sponsor Protocol Number: E7080-G000-201 | Start Date*: 2009-10-29 | |||||||||||
| Sponsor Name:Eisai Limited | |||||||||||||
| Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified... | |||||||||||||
| Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-000144-21 | Sponsor Protocol Number: UCL/10/0299 | Start Date*: 2011-10-05 | |||||||||||||||||||||
| Sponsor Name:University College London | |||||||||||||||||||||||
| Full Title: ION– Is ablative radiOiodine Necessary for low risk differentiated thyroid cancer patients | |||||||||||||||||||||||
| Medical condition: Patients with differentiated thyroid cancer who are classed as low risk | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2005-001618-42 | Sponsor Protocol Number: 20040273 | Start Date*: 2005-07-28 | |||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||
| Full Title: A Phase 2 Open-Label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer | |||||||||||||
| Medical condition: Locally advanced or metastatic thyroid cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) HU (Completed) DK (Completed) BE (Completed) AT (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001908-17 | Sponsor Protocol Number: 2021.40 | Start Date*: 2022-09-05 | |||||||||||
| Sponsor Name:Leiden University Medical Center | |||||||||||||
| Full Title: Neo- and adjuvant targeted therapy in BRAF-mutated anaplastic cancer of the thyroid (NEO-ATACT study) | |||||||||||||
| Medical condition: BRAF-mutated anaplastic thyroid cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-005199-27 | Sponsor Protocol Number: E7080-G000-211 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Eisai Ltd. | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily W... | |||||||||||||
| Medical condition: 131I-refractory differentiated thyroid cancer (DTC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
